amlodipine/candesartan (HL-068) / Daewoong Pharma - LARVOL DELTA

Bioequivalence Study (Candesartan 16 mg and Amlodipine 10 mg) (clinicaltrials.gov) - P1 | N=42 | Completed | Sponsor: HanAll BioPharma Co., Ltd. | Unknown status ➔ Completed

Trial completion • Cardiovascular • Hypertension

Noxa in Airway Epithelia Inhibits NF-κB Activation and the Development of Cigarette Smoke-induced Emphysema (ATS 2019) - "These results demonstrate that loss of Noxa enhances CS-induced lung inflammation, and transgenic expression of Noxa in airway epithelia mitigates CS- or LPS-induced pro-inflammatory responses and the development of emphysema induced by combined CS exposure and IAV infection. Thus, Noxa may have a therapeutic potential for COPD.Funded by: HL068111, ES015482, and F32 HL129749"

The Proline-Rich Domain of p53 Protects from Mucin Gene Expression at Baseline and After Short-Term but Not Chronic Wood Smoke Exposures (ATS 2019) - "These findings suggest that females with modified proline-rich domain show increased mucin gene expression in lung airways at baseline. While exposure to WS for 1 day caused higher mucin gene expression in p53AXXA mice this response was blunted over prolonged exposure. These findings suggest that susceptibility genes for WS exposure may not display a different phenotype for those who are exposed to pollutants over prolonged periods.Funded by: NIH Grant HL068111 and HL134370"